Navigation Links
InCode BioPharmaceutics Appoints New President and CEO

SAN FRANCISCO, Nov. 20 /PRNewswire/ -- InCode BioPharmaceutics, Inc., an emerging company in complement depletion, announced that it has appointed Kevin L. Stark, Ph.D. as President and Chief Executive Officer, effective immediately. Dr. Stark has more than 19 years experience as a biopharmaceutical researcher and executive, most recently as an Executive Director at Amgen, and Chief Operating Officer at iZumi Bio, Inc. His latest responsibilities included strategic operations within R&D, integration of mergers and acquisitions, licensing, and business development.

"We are very pleased to appoint Kevin Stark as our CEO," said Jay Lichter, Ph.D., Chairman of the Board. "We believe his experience, which spans basic research to executive management, will be instrumental as the company advances into drug development and seeks potential partnerships."

Dr. Stark received a Ph.D. in Pharmacology from the University of Washington, and a B.S. in Zoology from Colorado State University.

InCode also announced that William St. John has resigned as President and Chief Executive Officer, and will remain on the Board of Directors.

"We are very grateful to Bill for his vision in recognizing the promise of complement depletion in human disease, and his role in building the company to this point," said Carl-Wilhelm Vogel, MD, Ph.D., Founder and Board Member, from the Cancer Research Center of Hawaii.

In conjunction with this transition, the company will shift operations from the San Francisco, CA location to the Thousand Oaks, CA area.

About InCode

InCode's novel approach is focused on the selective interruption of the complement cascade. Activation of the complement cascade has been implicated in the pathogenesis of many inflammatory diseases, including rheumatoid arthritis, asthma, ischemia-reperfusion injury and age-related macular degeneration. Importantly, there is increased appreciation for the role of complement in certain types of cancer.

    For more information, contact:

This release was issued through eReleases(TM). For more information, visit

SOURCE InCode BioPharmaceutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Sangamo BioSciences Appoints Paul Cleveland to Its Board of Directors and Chair of Audit Committee
2. GeneNews appoints Canadian Colorectal Cancer Advisory Board
3. WuXi PharmaTech Appoints Ying Han to Its Board of Directors
4. TorreyPines Therapeutics Appoints Evelyn Graham Chief Executive Officer and a Member of the Board of Directors
5. Accumetrics Appoints John J. Young, MD Chief Medical Officer
6. Potentia Pharmaceuticals Appoints Johanna M. Seddon, M.D. and Janet Stoltz Sunness, M.D. to Scientific Advisory Board
7. Cynvec LLC(SM) Appoints Former Johnson & Johnson Executive Frank D. Stonebanks as President and Chief Executive Officer
8. Kendle Reappoints Former CFO Timothy M. Mooney to Board of Directors
9. NutraCea Appoints New Chief Financial Officer
10. Cardiac Science Appoints Dave Marver as Chief Operating Officer
11. Nutrition 21 Appoints Pam McWilliams, Vice President - General Manager of Direct Response
Post Your Comments:
(Date:6/23/2016)... (PRWEB) , ... June 23, 2016 , ... ... today announced the launch of the Supplyframe Design Lab . Located in ... to explore the future of how hardware projects are designed, built and brought ...
(Date:6/23/2016)... ... June 23, 2016 , ... In a new case report published today in ... patient who developed lymphedema after being treated for breast cancer benefitted from an injection ... for dealing with this debilitating, frequent side effect of cancer treatment. , ...
(Date:6/23/2016)...  Blueprint Bio, a company dedicated to identifying, protecting ... has closed its Series A funding round, according to ... "We have received a commitment from Forentis Fund that ... meet our current goals," stated Matthew Nunez . ... complete validation on the current projects in our pipeline, ...
(Date:6/23/2016)... , June 23, 2016 On ... session at 4,833.32, down 0.22%; the Dow Jones Industrial Average ... 500 closed at 2,085.45, down 0.17%. has initiated coverage ... INFI ), Nektar Therapeutics (NASDAQ: NKTR ), Aralez ... Inc. (NASDAQ: BIND ). Learn more about these ...
Breaking Biology Technology:
(Date:5/20/2016)... May 20, 2016  VoiceIt is excited to ... VoicePass. By working together, VoiceIt and ... VoiceIt and VoicePass take slightly different approaches to ... both security and usability. ... this new partnership. "This marketing and ...
(Date:5/9/2016)... 9, 2016 Elevay is currently ... expanding freedom for high net worth professionals seeking travel ... globally connected world, there is still no substitute for ... duplicate sealing your deal with a firm handshake. This ... taking advantage of citizenship via investment programs like those ...
(Date:4/28/2016)... First quarter 2016:   , ... the first quarter of 2015 The gross margin was ... 18.8) and the operating margin was 40% (-13) Earnings ... flow from operations was SEK 249.9 M (21.2) , ... SEK 7,000-8,500 M. The operating margin for 2016 is ...
Breaking Biology News(10 mins):